Nifty
Sensex
:
:
11937.65
40707.31
40.85 (0.34%)
162.94 (0.40%)

Pharmaceuticals & Drugs - Domestic

Rating :
77/99  (View)

BSE: 539523 | NSE: ALKEM

2650.80
-14.90 (-0.56%)
21-Oct-2020 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  2670.00
  •  2678.90
  •  2637.00
  •  2665.70
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  72479
  •  1921.27
  •  3090.00
  •  1881.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 31,705.65
  • 23.25
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 32,314.29
  • 0.94%
  • 4.82

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 62.43%
  • 0.22%
  • 20.13%
  • FII
  • DII
  • Others
  • 3.92%
  • 12.49%
  • 0.81%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.31
  • 11.12
  • 9.29

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.79
  • 11.54
  • 7.87

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.32
  • 8.73
  • 21.34

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 28.75
  • 30.69

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 4.64
  • 4.61

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 20.06
  • 20.05

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
2,003
1,850
8%
2,049
1,854
11%
2,182
1,926
13%
2,264
1,919
18%
Expenses
1,470
1,585
-7%
1,746
1,619
8%
1,729
1,613
7%
1,811
1,555
16%
EBITDA
533
264
102%
303
235
29%
453
314
45%
453
364
24%
EBIDTM
27%
14%
14%
13%
21%
16%
20%
19%
Other Income
44
17
149%
27
28
-1%
28
8
268%
31
25
28%
Interest
17
16
6%
14
7
115%
17
15
11%
18
16
8%
Depreciation
67
56
20%
81
57
42%
59
48
25%
56
46
23%
PBT
493
210
135%
235
199
18%
405
258
57%
410
326
26%
Tax
70
23
206%
44
28
55%
15
53
-72%
29
66
-55%
PAT
423
187
126%
192
170
12%
390
205
90%
381
260
46%
PATM
21%
10%
7%
9%
18%
11%
17%
14%
EPS
35.38
15.66
126%
16.02
14.26
12%
32.61
17.18
90%
31.82
21.77
46%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
8,498
8,344
7,357
6,392
5,688
4,925
3,743
3,126
2,495
2,016
1,691
Net Sales Growth
13%
13%
15%
12%
15%
32%
20%
25%
24%
19%
 
Cost Of Goods Sold
7,117
2,959
2,603
1,986
1,808
1,631
1,453
1,168
867
646
597
Gross Profit
1,382
5,385
4,754
4,405
3,880
3,294
2,290
1,958
1,628
1,370
1,094
GP Margin
16%
65%
65%
69%
68%
67%
61%
63%
65%
68%
65%
Total Expenditure
6,756
6,871
6,242
5,383
4,689
4,072
3,322
2,716
2,133
1,640
1,404
Power & Fuel Cost
-
130
121
113
86
66
53
60
53
51
38
% Of Sales
-
2%
2%
2%
2%
1%
1%
2%
2%
3%
2%
Employee Cost
-
1,505
1,362
1,192
1,004
861
646
532
412
303
267
% Of Sales
-
18%
19%
19%
18%
17%
17%
17%
17%
15%
16%
Manufacturing Exp.
-
765
806
839
692
550
368
306
265
235
196
% Of Sales
-
9%
11%
13%
12%
11%
10%
10%
11%
12%
12%
General & Admin Exp.
-
526
513
470
378
331
238
185
180
139
106
% Of Sales
-
6%
7%
7%
7%
7%
6%
6%
7%
7%
6%
Selling & Distn. Exp.
-
854
726
675
596
504
435
367
295
226
167
% Of Sales
-
10%
10%
11%
10%
10%
12%
12%
12%
11%
10%
Miscellaneous Exp.
-
131
111
108
124
128
128
98
60
40
167
% Of Sales
-
2%
2%
2%
2%
3%
3%
3%
2%
2%
2%
EBITDA
1,742
1,473
1,115
1,009
999
853
422
410
362
375
287
EBITDA Margin
20%
18%
15%
16%
18%
17%
11%
13%
15%
19%
17%
Other Income
130
104
88
115
112
240
181
165
167
145
113
Interest
66
65
55
55
45
71
81
93
88
58
41
Depreciation
264
253
193
143
101
93
71
52
40
29
27
PBT
1,543
1,260
955
926
965
928
451
430
402
433
331
Tax
157
110
181
288
60
176
59
-5
18
28
36
Tax Rate
10%
9%
19%
31%
6%
19%
13%
-1%
4%
6%
11%
PAT
1,385
1,127
761
631
892
742
392
435
384
407
296
PAT before Minority Interest
1,366
1,149
774
638
905
752
392
435
384
406
296
Minority Interest
-19
-22
-13
-7
-13
-11
0
0
0
1
0
PAT Margin
16%
14%
10%
10%
16%
15%
10%
14%
15%
20%
17%
PAT Growth
68%
48%
21%
-29%
20%
89%
-10%
13%
-6%
38%
 
EPS
115.82
94.24
63.59
52.75
74.58
62.01
32.74
36.40
32.09
33.99
24.71

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
6,161
5,439
4,864
4,468
3,692
3,003
2,585
2,177
1,820
1,434
Share Capital
24
24
24
24
24
24
12
12
12
12
Total Reserves
6,135
5,414
4,839
4,443
3,668
2,979
2,573
2,165
1,808
1,422
Non-Current Liabilities
-542
-262
-359
-401
-306
197
324
362
525
434
Secured Loans
149
220
122
175
112
33
232
256
309
246
Unsecured Loans
10
12
9
7
11
0
0
0
0
0
Long Term Provisions
222
201
150
102
83
67
42
44
180
162
Current Liabilities
3,243
2,190
2,383
1,690
1,538
2,006
1,403
1,732
1,121
982
Trade Payables
954
962
961
741
580
466
306
288
276
168
Other Current Liabilities
555
428
520
339
366
327
201
188
111
87
Short Term Borrowings
1,504
671
761
472
464
1,129
845
1,210
670
663
Short Term Provisions
230
129
141
137
127
84
50
46
63
64
Total Liabilities
9,011
7,501
7,010
5,872
5,018
5,291
4,311
4,271
3,466
2,852
Net Block
2,908
2,530
2,284
1,797
1,450
1,374
1,170
1,072
919
693
Gross Block
3,607
3,026
2,604
1,977
1,539
1,745
1,170
1,072
919
693
Accumulated Depreciation
699
496
320
180
89
371
0
0
0
0
Non Current Assets
3,515
3,284
2,997
2,955
2,250
2,953
2,709
2,115
2,153
1,313
Capital Work in Progress
363
493
381
299
172
111
0
0
0
0
Non Current Investment
92
96
98
259
234
420
338
410
299
6
Long Term Loans & Adv.
106
119
141
193
142
542
418
339
259
154
Other Non Current Assets
47
47
92
406
251
506
783
293
677
460
Current Assets
5,496
4,216
4,013
2,917
2,769
2,338
1,602
2,156
1,312
1,539
Current Investments
170
228
346
294
274
61
250
67
24
48
Inventories
1,819
1,500
1,442
1,206
909
784
620
554
385
251
Sundry Debtors
1,649
1,248
1,080
714
568
527
367
318
247
171
Cash & Bank
1,092
662
577
399
781
791
206
995
514
990
Other Current Assets
766
173
177
133
237
175
159
221
143
79
Short Term Loans & Adv.
482
405
391
171
141
115
110
115
80
40
Net Current Assets
2,253
2,026
1,630
1,227
1,231
332
200
424
192
0
Total Assets
9,011
7,501
7,010
5,872
5,018
5,291
4,311
4,271
3,466
2,852

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
585
777
266
471
726
328
290
78
159
148
PBT
1,260
955
926
965
928
514
430
402
433
331
Adjustment
256
216
116
33
-14
16
7
-31
-33
-18
Changes in Working Capital
-647
-143
-573
-263
10
-96
-36
-183
-145
-99
Cash after chg. in Working capital
868
1,029
469
735
924
434
401
188
256
215
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-283
-251
-203
-264
-198
-106
-111
-110
-97
-67
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-741
-314
-357
-286
202
-237
350
-404
-248
-823
Net Fixed Assets
-311
-342
-531
-390
161
-112
-103
-214
-207
Net Investments
-260
-151
-27
-360
-87
-130
-361
-207
-319
Others
-170
179
201
464
129
5
815
17
278
Cash from Financing Activity
79
-379
85
-138
-927
-52
-600
356
-11
779
Net Cash Inflow / Outflow
-77
84
-7
47
1
39
41
30
-100
104
Opening Cash & Equivalents
249
167
167
127
124
101
57
26
124
20
Closing Cash & Equivalent
176
249
167
167
127
140
101
57
26
124

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
515
455
407
374
309
251
216
182
152
0
ROA
14%
11%
10%
17%
15%
8%
10%
10%
13%
10%
ROE
20%
15%
14%
22%
22%
14%
18%
19%
25%
21%
ROCE
19%
16%
18%
21%
23%
13%
14%
15%
19%
16%
Fixed Asset Turnover
3.74
3.80
3.75
3.33
3.07
2.65
2.89
2.59
2.57
2.49
Receivable days
43
40
38
40
40
42
39
40
37
36
Inventory Days
49
50
56
66
61
66
66
67
56
53
Payable days
52
60
61
52
50
46
43
49
50
47
Cash Conversion Cycle
39
30
33
54
51
63
62
57
43
42
Total Debt/Equity
0.28
0.17
0.21
0.15
0.18
0.43
0.44
0.71
0.55
0.00
Interest Cover
20
18
18
22
14
7
6
6
8
9

News Update


  • Alkem Laboratories - Quarterly Results
    7th Aug 2020, 13:38 PM

    Read More
  • Alkem Laboratories launches Favipiravir for COVID-19 treatment
    6th Aug 2020, 09:12 AM

    The company has launched Favipiravir under the brand name ‘Alfluenza’ in India

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.